A pharmacoeconomic analysis of ibrutinib in the treatment of mantle cell lymphoma

Abstract

Mantle cell lymphoma (MCL) accounts for approximately 2% to 10% of the total number of lymphatic system tumours, the incidence rate in Western Europe and Scandinavia is approximately 0,5/100 000 people. Most MCL cases are aggressive lymphomas, and overall survival is in the range of 3 to 5 years, while the disease is characterized by a short time to progression. The objective of this study was to determine the better treatment option between temsirolimus and ibrutinib in the treatment of MCL, in terms of pharmacoeconomic analysis, by means of comparative cost-effectiveness assessment. The cost-effectiveness results obtained in this temsirolimus versus ibrutinib comparative study demonstrated that ibrutinib therapy was associated with lower cost per effectiveness unit when life years gained and quality-adjusted life years were utilized as effectiveness criteria. Obtained budget impact analysis results revealed that ibrutinib therapy resulted in budget saving.

Medicamentos Oncohematológicos evaluados por GENESIS (2007-2018)

“…DT 01/2019 y 22,40 meses. El tratamiento con bentuximab vedotina en pacientes con LACG implicó una mejora de 0,54 AVACs, mientras que la administración de temsirolimus en pacientes con LCM implicó una mejora de 0,59 AVACs (7,27,28) . Fuente: GENESIS (7) ; Babashov et al (2017) (27) y Komarov et al (2015) (28) .…”